| Nina Petroff, MD | |
|
23250 Chagrin Blvd, Suite 350, Beachwood, OH 44122-5470 | |
| (216) 765-7474 | |
| (216) 765-7484 |
| Full Name | Nina Petroff |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 46 Years |
| Location | 23250 Chagrin Blvd, Beachwood, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396836086 | NPI | - | NPPES |
| 0866684 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | 35051014P (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Parker Skin And Aesthetic Clinic Inc | 4587614813 | 11 |
News Archive
The drug industry's decision to agree to $80 billion in concessions to the White House was short-sighted, will hurt drug manufacturers and their customers, and "has all the markings of a deal gone sour," House Minority Leader John Boehner wrote Monday to his former colleague, Billy Tauzin, who now heads the Pharmaceutical Research and Manufacturers of America.
A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.
Using evidence found in baby teeth, researchers from The Senator Frank R. Lautenberg Environmental Health Sciences Laboratory and The Seaver Autism Center for Research and Treatment at Mount Sinai found that differences in the uptake of multiple toxic and essential elements over the second and third trimesters and early postnatal periods are associated with the risk of developing autism spectrum disorders (ASD), according to a study published June 1 in the journal Nature Communications.
For millions of Americans, their world is dissolving into an unrecognizable blur. Diabetic retinopathy is an eye disease affecting one-third of the estimated 30 million Americans who struggle with diabetes. As the patients' vision slowly fades, it never recovers and few treatments are available.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
› Verified 6 days ago
| Entity Name | Parker Skin & Aesthetic Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609894575 PECOS PAC ID: 4587614813 Enrollment ID: O20050125000580 |
News Archive
The drug industry's decision to agree to $80 billion in concessions to the White House was short-sighted, will hurt drug manufacturers and their customers, and "has all the markings of a deal gone sour," House Minority Leader John Boehner wrote Monday to his former colleague, Billy Tauzin, who now heads the Pharmaceutical Research and Manufacturers of America.
A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.
Using evidence found in baby teeth, researchers from The Senator Frank R. Lautenberg Environmental Health Sciences Laboratory and The Seaver Autism Center for Research and Treatment at Mount Sinai found that differences in the uptake of multiple toxic and essential elements over the second and third trimesters and early postnatal periods are associated with the risk of developing autism spectrum disorders (ASD), according to a study published June 1 in the journal Nature Communications.
For millions of Americans, their world is dissolving into an unrecognizable blur. Diabetic retinopathy is an eye disease affecting one-third of the estimated 30 million Americans who struggle with diabetes. As the patients' vision slowly fades, it never recovers and few treatments are available.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nina Petroff, MD 23250 Chagrin Blvd, Suite 350, Beachwood, OH 44122-5470 Ph: (216) 765-7474 | Nina Petroff, MD 23250 Chagrin Blvd, Suite 350, Beachwood, OH 44122-5470 Ph: (216) 765-7474 |
News Archive
The drug industry's decision to agree to $80 billion in concessions to the White House was short-sighted, will hurt drug manufacturers and their customers, and "has all the markings of a deal gone sour," House Minority Leader John Boehner wrote Monday to his former colleague, Billy Tauzin, who now heads the Pharmaceutical Research and Manufacturers of America.
A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.
Using evidence found in baby teeth, researchers from The Senator Frank R. Lautenberg Environmental Health Sciences Laboratory and The Seaver Autism Center for Research and Treatment at Mount Sinai found that differences in the uptake of multiple toxic and essential elements over the second and third trimesters and early postnatal periods are associated with the risk of developing autism spectrum disorders (ASD), according to a study published June 1 in the journal Nature Communications.
For millions of Americans, their world is dissolving into an unrecognizable blur. Diabetic retinopathy is an eye disease affecting one-third of the estimated 30 million Americans who struggle with diabetes. As the patients' vision slowly fades, it never recovers and few treatments are available.
Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.
› Verified 6 days ago
Rachel Mistur, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3737 Park East Dr Ste 109, Beachwood, OH 44122 Phone: 216-464-7333 Fax: 216-464-2696 | |
Sarah Gabros, DO Dermatology Medicare: Medicare Enrolled Practice Location: 3737 Park East Dr Ste 109, Beachwood, OH 44122 Phone: 216-464-7333 | |
Kirsten Trotter Lynch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3737 Park East Dr, Suite 109, Beachwood, OH 44122 Phone: 216-464-7333 Fax: 216-464-2696 | |
Dr. Robert S. Haber, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 26949 Chagrin Blvd, #300, Beachwood, OH 44122 Phone: 216-932-5200 Fax: 216-932-5212 | |
Mikhenan Horvath, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3737 Park East Dr Ste 109, Beachwood, OH 44122 Phone: 216-464-7333 | |
Beno Michel, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 23250 Chagrin Blvd, Suite 350, Beachwood, OH 44122 Phone: 216-765-7474 Fax: 216-765-7484 |